NCT02051218 2025-12-30
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
Swiss Cancer Institute
Phase 3 Active not recruiting
Clinical Trials
8 trialsNCT03869762 2024-09-25
DICE
Cancer Trials Ireland
Phase 2 Terminated
NCT02758132 2019-11-08
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
University of Hawaii
Phase 2 Terminated
NCT01419717 2019-09-24
Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
Amgen
Phase 3 Completed
NCT00838201 2018-10-18
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
Amgen
Phase 3 Completed
NCT00089674 2018-10-17
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer
Amgen
Phase 3 Completed
NCT00925600 2017-05-30
Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
Amgen
Phase 3 Completed
NCT00950911 2014-02-11
Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
Amgen
Phase 3 Completed